Ongoing Cancer R&D Efforts at Tosk, Inc.

Tosk pic
Tosk
Image: Tosk.com

Brian Frenzel is an accomplished private investor and serial entrepreneur who has excelled in the life sciences industry. Over the course of a career spanning more than 30 years, Brian Frenzel has successfully led a number of companies and now works with Tosk, Inc., SanBio Co. Ltd., and AnVent Enterprises.

Tosk, Inc. is a drug discovery and development company committed to improving outcomes for patients suffering from the painful and debilitating side effects of widely-used cancer therapies and to enhance treatment options for patients who have not benefited from therapy. Tosk has two patented drugs in development, TK-90 for mucositis side effect reduction and TK-39 for cardiotoxicity side effect reduction, and has two other drug discovery programs underway. Tosk calls them CompanionTM drugs because they are designed to be administered alongside existing therapies.

The Company’s other initiatives include TK-88, which is intended to selectively block the adverse side effects of platinum-based drugs such as carboplatin, cisplatin, and oxaliplatin, and TK-kRAS which targets the human kRAS oncogene. Platinum drugs are effective, front line therapies for ovarian, breast, cervical, lung, head and neck, endometrial, and esophageal cancers which, unfortunately, also cause kidney damage, peripheral nerve damage, and hearing loss.

Tosk’s mutant kRAS gene initiative focuses on blocking the effects of this important cancer growth promoter. Also, according to the US National Cancer Institute, an estimated 40 percent of cancer patients worldwide carry an autogenic kRAS gene that effectively negates the efficacy of EGFR-inhibitor cancer therapies, such as Erbitux® and Vectibix®, to fight the disease. A kRAS product could both prove effective in treating kRAS positive cancers, including 90% of pancreatic and 45% of colon cancers, as well as making EGFR inhibitors effective in patients who currently do not benefit from treatment.

Advertisements

Tosk Initiates Proof of Concept (POC) Studies for Cancer Drug TK-90

 

Acute Treatment of Traumatic Brain Injury

SanBio pic
SanBio
Image: san-bio.com

Biotechnology executive Brian Frenzel is a director at SanBio, Inc., a cell therapy developer focusing primarily on neurodegenerative diseases. Under the leadership of Brian Frenzel, SanBio, Inc. has initiated research and development projects into traumatic brain injury (TBI).

TBI is a serious medical problem that can result in disability and death. Acute treatment following TBI usually focuses on life support and reducing secondary injuries that can arise from altered brain function. For example, physicians may insert a device in the brain cavity to stabilize intracranial pressure, or they may place the patient in a medically induced coma to minimize agitation. Acute treatments may also include mood stabilizers such as carbamazapine which can be used to control agitation, while atypical antidepressants such as amitryptyline can mitigate certain aggressive behaviors.

Other than physical therapy, there currently is no effective treatment for long term disability resulting from TBI. SanBio is developing a cell therapy product derived from mesenchymal stem cells to help patients recover from TBI disability. The product, known as SB623, is currently undergoing clinical studies in the US and Japan.

Cardiomyopathy in Chemotherapy Patients

As president and CEO of Tosk, Inc., Brian Frenzel oversees research into blocking drug side effects that can be dose-limiting and potentially fatal. Focused largely on the chemotherapy field, Brian Frenzel has managed the development of compounds that reduces the cardiotoxicity of drugs such as doxorubicin, also known as Adriamycin.

Designed to kill cancer cells throughout the body, chemotherapies also attack healthy cells and cause painful and debilitating side effects. When these drugs attack the heart muscle, the patient may develop a condition known as cardiomyopathy. This condition can result in arrhythmia or chronic disease of the heart. In some cases, chemotherapy-induced cardiotoxicity can lead congestive heart failure, which is potentially fatal.

Most chemotherapy-related cardiomyopathies develop as a result of the use of doxorubicin or its derivatives. Since the damage to the heart is permanent, the risk of heart disease limits the recommended lifetime dose of doxorubicin to 450-550 milligrams per square meter, or about a gram for a typical patient. Even at this limited dose, 3-5% of patients experience congestive heart failure, and 25% have some degree of cardiomyopathy.

Tosk is developing drugs to reduce or eliminate the cardiotoxicity of doxorubicin and thereby improve outcomes for cancer patients.